Cell-Targeted Regulation of Gene Expression through Synthetic RNA Devices

> Thesis by James Vincent Vowles

In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy



CALIFORNIA INSTITUTE OF TECHNOLOGY

Pasadena, California

2014

(Defended May 12, 2014)

© 2014 James Vincent Vowles All Rights Reserved

Acknowledgements

This thesis would not have been possible without the unending support of Professor Christina Smolke. She has created a laboratory that nurtures young scientists while producing research of the highest caliber. Her insights have guided me through countless struggles and helped me develop as a scientist.

My deep appreciation goes out to all the past and present members of the Smolke laboratory. Every one of them has helped me in some way, large or small. Their breadth of expertise has been immensely valuable, so that when I am tackling a new challenge I can benefit from their greater skills and knowledge rather than going it alone. I am especially indebted to Maung Win, whose initial development of the ribozyme switch platform helped elevate the lab to the forefront of synthetic biology and provided me with a starting point for my project. For my entire graduate career I have been following the trail that he blazed. I also owe much of my success to Drew Kennedy, my partner on this project and my friend for nearly seven years. Drew has challenged me to be a better scientist, pointing out the holes in my reasoning and helping me to see the way forward from stubborn problems.

My thanks go to the members of my thesis committee, Professors Peter Dervan, Doug Rees, and Carl Parker. They offered fresh perspectives on my research and their support helped me leave behind failed projects to focus on more promising pursuits. Thanks also to Professor Harry Gray and Craig Wiggenhorn for facilitating the videoconferences that allowed me to meet with my committee without having to travel from Stanford to Caltech. Finally, I must thank my friends and family. They supported me through grad school's most trying times, accepting my greatly decreased availability when my research demanded it. No one experienced this more strongly than my partner Ashley, who has often felt at war with the lab for my attention. She is the most loving and understanding person I have ever known and her support has been immeasurably valuable.

Abstract

The ability to interface with and program cellular function remains a challenging research frontier in biotechnology. Although the emerging field of synthetic biology has recently generated a variety of gene-regulatory strategies based on synthetic RNA molecules, few strategies exist through which to control such regulatory effects in response to specific exogenous or endogenous molecular signals. Here, we present the development of an engineered RNA-based device platform to detect and act on endogenous protein signals, linking these signals to the regulation of genes and thus cellular function.

We describe efforts to develop an RNA-based device framework for regulating endogenous genes in human cells. Previously developed RNA control devices have demonstrated programmable ligand-responsive genetic regulation in diverse cell types, and we attempted to adapt this class of cis-acting control elements to function in trans. We divided the device into two strands that reconstitute activity upon hybridization. Device function was optimized using an *in vivo* model system, and we found that device sequence is not as flexible as previously reported. After verifying the *in vitro* activity of our optimized design, we attempted to establish gene regulation in a human cell line using additional elements to direct device stability, structure, and localization. The significant limitations of our platform prevented endogenous gene regulation.

We next describe the development of a protein-responsive RNA-based regulatory platform. Employing various design strategies, we demonstrated functional devices that both up- and downregulate gene expression in response to a heterologous protein in a human cell line. The activity of our platform exceeded that of a similar, small-molecule-

V

responsive platform. We demonstrated the ability of our devices to respond to both cytoplasmic- and nuclear-localized protein, providing insight into the mechanism of action and distinguishing our platform from previously described devices with more restrictive ligand localization requirements. Finally, we demonstrated the versatility of our device platform by developing a regulatory device that responds to an endogenous signaling protein.

The foundational tool we present here possesses unique advantages over previously described RNA-based gene-regulatory platforms. This genetically encoded technology may find future applications in the development of more effective diagnostic tools and targeted molecular therapy strategies.

TABLE OF CONTENTS

Acknowledgements	iii
Abstract	v
Table of Contents	vii
List of Figures	ix
CHAPTER 1: Introduction	I-1
RNA is a versatile regulatory biomolecule	I-2
Engineered RNA devices in eukaryotes enable dynamic modulation of gene	expression in
response to molecular and environmental signals	I-3
Ligand-responsive ribozyme switches	I-6
Applications	I-11
Scope of thesis	I-12
References	I-14
CHAPTER 2: Development of an RNA device framework that targets e	ndogenous
genes in human cells	II-1
Abstract	II-2
Abstract	
	II-3
Introduction	II-3 II-8
Introduction Results	II-3 II-8 II-8
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells	II-3 II-8 II-8 II-11
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells Characterization of initial trans-ribozyme designs in a human cell line	II-3 II-8 II-8 II-11 II-15
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells Characterization of initial trans-ribozyme designs in a human cell line Cis-ribozymes as a model for optimizing <i>in vivo</i> cleavage activity	II-3 II-8 II-8 II-11 II-11 II-15 II-17
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells Characterization of initial trans-ribozyme designs in a human cell line Cis-ribozymes as a model for optimizing <i>in vivo</i> cleavage activity Characterization of Type I cis-ribozymes in a human cell line	II-3 II-8 II-8 II-11 II-11 II-15 II-17 II-18
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells Characterization of initial trans-ribozyme designs in a human cell line Cis-ribozymes as a model for optimizing <i>in vivo</i> cleavage activity Characterization of Type I cis-ribozymes in a human cell line Development of an improved trans-ribozyme	II-3 II-8 II-8 II-11 II-15 II-15 II-17 II-18 irect stability,
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells Characterization of initial trans-ribozyme designs in a human cell line Cis-ribozymes as a model for optimizing <i>in vivo</i> cleavage activity Characterization of Type I cis-ribozymes in a human cell line Development of an improved trans-ribozyme Incorporation of ancillary elements in the trans-ribozyme transcript to d	II-3 II-8 II-8 II-11 II-15 II-15 II-17 II-18 irect stability, II-20
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells Characterization of initial trans-ribozyme designs in a human cell line Cis-ribozymes as a model for optimizing <i>in vivo</i> cleavage activity Characterization of Type I cis-ribozymes in a human cell line Development of an improved trans-ribozyme. Incorporation of ancillary elements in the trans-ribozyme transcript to d structure, processing, and localization	II-3 II-8 II-8 II-11 II-15 II-15 II-17 II-17 II-18 irect stability, II-20 II-23
Introduction Results Design of a trans-ribozyme-based regulatory element in human cells Characterization of initial trans-ribozyme designs in a human cell line Cis-ribozymes as a model for optimizing <i>in vivo</i> cleavage activity Characterization of Type I cis-ribozymes in a human cell line Development of an improved trans-ribozyme Incorporation of ancillary elements in the trans-ribozyme transcript to d structure, processing, and localization Discussion	II-3 II-8 II-8 II-11 II-15 II-15 II-17 II-17 II-18 irect stability, II-20 II-23 II-27

Supplementary Tables II-41
CHAPTER 3: Development of an RNA device framework that responds to proteins
in human cells III-1
Abstract III-2
Introduction III-3
Results
Design of protein-responsive ribozyme switch platforms III-7
Initial characterization of protein-responsive ribozyme switches in a human cell line
Development of an improved genetic system for quantitative characterization of
ribozyme switch activity in vivo III-15
MS2 variants result in optimization of switch sensitivity to ligand III-21
Protein ligand localization allows probing of ribozyme switch mechanism of action
Development of ribozyme switch platforms responsive to additional proteins III-34
Discussion
Methods III-49
Acknowledgements
References
Supplementary TablesIII-67
CHAPTER 4: ConclusionsIV-1
ReferencesIV-6

List of Figures

Figure 1.1	The phosphodiester isomerization mechanism of hammerhead
	ribozymes

- Figure 1.2 Assembly of a ribozyme switch from modular components
- Figure 1.3 Ligand binding stabilizes the aptamer-formed conformation
- Figure 2.1 Structure and function of the trans-ribozyme
- Figure 2.2 Structures of trans-ribozymes bound to target sequences
- Figure 2.3 Trans-ribozyme and target gene characterization system
- Figure 2.4 Activity of trans-ribozymes
- Figure 2.5 Structures of cis-ribozymes used to model trans-ribozyme activity
- Figure 2.6 Activity of type I cis-ribozymes
- Figure 2.7 The improved trans-ribozyme
- Figure 2.8 Trans-ribozyme ancillary elements
- Figure 2.9 Activity of trans-ribozymes with ancillary elements
- Figure 2.10 Plasmid maps
- Figure 3.1 MS2-responsive ribozyme switch designs
- Figure 3.2 Protein-responsive ribozyme switch characterization system
- Figure 3.3 Activity of MS2-A designs
- Figure 3.4 Activity of MS2-B, MS2-C, and MS2-D designs
- Figure 3.5 Histograms of transiently transfected and stably integrated fluorescent constructs
- Figure 3.6 Effects of transient transfection of stable cell lines expressing a fluorescent reporter protein

- Figure 3.7 Activity of ribozyme switches with optimized ligands
- Figure 3.8 Subcellular localization of ligands with and without localization signals
- Figure 3.9 Activity of ribozyme switches with ligands with and without localization signals
- Figure 3.10 Confocal fluorescence microscopy of ligands with and without localization signals
- Figure 3.11 Activity of ribozyme switches with improved localized ligands
- Figure 3.12 Activity of ribozyme switches with improved localized ligands over a range of ligand concentrations
- Figure 3.13 Design and testing of PP7-responsive switch designs
- Figure 3.14 Design and testing of lambda-N-responsive switch designs
- Figure 3.15 NF-κB-responsive ribozyme switch characterization system
- Figure 3.16 Design and testing of NF-kB-responsive switch designs
- Figure 3.17 Design and testing of β -catenin-responsive switch designs
- Figure 3.18 Plasmid maps